Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.41 |
| ▸ | FNTA | P49354 | 5/20 | 0.39 |
| ▸ | FNTB | P49356 | 5/20 | 0.39 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 2/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13445975 | 0.87 | ALB (0.42) | FOLH1ALB | |
| SCHEMBL13464206 | 0.87 | ALB (0.42) | FOLH1ALB | |
| SCHEMBL5501792 | 0.82 | FOLH1 (0.49) | FOLH1FNTAFNTBC3AR1PTGS1 | |
| SCHEMBL24630046 | 0.81 | NOD1 (0.48) | FOLH1C3AR1GNPATALBNOD1 | |
| SCHEMBL29072118 | 0.81 | NOD1 (0.48) | FOLH1C3AR1GNPATALBNOD1 | |
| SCHEMBL29072117 | 0.81 | NOD1 (0.48) | FOLH1C3AR1GNPATALBNOD1 | |
| SCHEMBL3517847 | 0.80 | NOD1 (0.52) | FNTAFNTBPTGS1PTGS2NOD1 | |
| SCHEMBL29335571 | 0.80 | NOD1 (0.50) | FOLH1C3AR1GNPATALBNOD1 | |
| SCHEMBL16273731 | 0.79 | FOLH1 (0.49) | FOLH1FNTAFNTBPTGS1PTGS2 | |
| SCHEMBL15919123 | 0.79 | FOLH1 (0.49) | FOLH1FNTAFNTBPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250248994-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250073348-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2025-03-06 | — | — | US | disclosed |
| US-12194321-B2 | Camptothecin conjugates | SEAGEN INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20230036256-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230036256-A1 | CAMPTOTHECIN CONJUGATES | DCLRE1A, TOP2A, PAICS | FOLH1 92/4885FNTA 645/4885FNTB 807/4885 |
| US-20250248994-A1 | CAMPTOTHECIN CONJUGATES | DCLRE1A, TOP2A, PAICS | FOLH1 92/4885FNTA 645/4885FNTB 807/4885 |
| US-20250073348-A1 | CAMPTOTHECIN CONJUGATES | DCLRE1A, TOP2A, PAICS | FOLH1 92/4885FNTA 645/4885FNTB 807/4885 |
| US-12194321-B2 | Camptothecin conjugates | DCLRE1A, TOP2A, PAICS | FOLH1 92/4885FNTA 645/4885FNTB 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.